Entrez Gene

General information | Literature | Expression | Regulation | Variant | Interaction

Basic Information
Gene ID	6532
Name	SLC6A4
Synonym	5-HTT\|5-HTTLPR\|5HTT\|HTT\|OCD1\|SERT\|SERT1\|hSERT;solute carrier family 6 (neurotransmitter transporter, serotonin), member 4;SLC6A4;solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
Definition	5-hydroxytryptamine transporter\|5HT transporter\|Na+/Cl- dependent serotonin transporter\|sodium-dependent serotonin transporter
Position	17q11.2
Gene Type	protein-coding
PAH Type	Description
HPH	Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.
PAH	Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease.
PAH	Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.
PAH	Allelic variation in the serotonin transporter (5HTT) gene contributes to idiopathic pulmonary hypertension in children.
PAH	Genetic association of the serotonin transporter in pulmonary arterial hypertension.
PAH	Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.
PAH	Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure.
PAH	"Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease."
PAH	Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease.
PAH	Association study of serotonin transporter gene polymorphisms and ventricular septal defects related possible pulmonary arterial hypertension in Chinese population.
	More detail of all Mouse literatures about SLC6A4
Pathways and Diseases
Pathway	5HT2 type receptor mediated signaling pathway;PANTHER;P04374
Pathway	5HT3 type receptor mediated signaling pathway;PANTHER;P04375
Pathway	5HT1 type receptor mediated signaling pathway;PANTHER;P04373
Pathway	5HT4 type receptor mediated signaling pathway;PANTHER;P04376
Disease	ADHD;GAD
Disease	major depression;GAD
Disease	obsessive-compulsive disorder;GAD
Disease	decision making;GAD
Disease	depression depressive disorder, major;GAD
Disease	aggressive behavior;GAD
Disease	Depression;FunDO
Disease	Hypertension, Pulmonary;FunDO
Disease	personality disorders;GAD
Disease	anorexia nervosa;GAD
Disease	Sudden infant death syndrome;FunDO
Disease	IMMUNE;GAD
Disease	Parkinson's disease;GAD
Disease	depressive disorder, major;GAD
Disease	Colon cancer;FunDO
Disease	mood disorders;GAD
Disease	PSYCH;GAD
Disease	chronic obstructive pulmonary disease;GAD
Disease	personality traits;GAD
Disease	Psychotic disorder;FunDO
Disease	Anxiety-related personality traits;OMIM
Disease	decision-making memory impairment;GAD
Disease	affective disorder;GAD
Disease	chronic fatigue syndrome;GAD
Disease	serotonin;GAD
Disease	major and bipolar depressives;GAD
Disease	brain function;GAD
Disease	mania, antidepressant-induced;GAD
Disease	alcohol use;GAD
Disease	unipolar disorder;GAD
Disease	smoking;GAD
Disease	temporomandibular joint pain;GAD
Disease	substance abuse;GAD
Disease	anxiety disorders;GAD
Disease	Atherosclerosis;FunDO
Disease	Obsessive-compulsive disorder 1;OMIM
Disease	Irritable Bowel Syndrome;GAD
Disease	psychosis, alcoholic;GAD
Disease	Migraine;FunDO
Disease	severe hyperkinetic disorders;GAD
Disease	brain electrical response;GAD
Disease	Ulcerative colitis;FunDO
Disease	bipolar affective disorder;GAD
Disease	Herpes;FunDO
Disease	adverse neonatal outcomes birth weight neuromotor symptoms respiratory distress syndrome, neonatal;GAD
Disease	sleep disorders;GAD
Disease	stroke, ischemic;GAD
Disease	Dermatitis;FunDO
Disease	Sexual Dysfunction, Physiological;GAD
Disease	anxiety-related traits;GAD
Disease	bipolar and unipolar disorder;GAD
Disease	eating disorder;GAD
Disease	Drug abuse;FunDO
Disease	Panic disorder;FunDO
Disease	psychoses;GAD
Disease	suicide;GAD
Disease	anxiety disorder migraine;GAD
Disease	suicide family history;GAD
Disease	attention deficit hyperactivity disorder;GAD
Disease	Bipolar disorder;FunDO
Disease	harm avoidance behaviour in an elderly population.;GAD
Disease	Anxiety and hostility and depression;GAD
Disease	schizophrenia;GAD
Disease	chronic obstructive pulmonary disease/COPD;GAD
Disease	Obsessive-compulsive disorder;FunDO
Disease	body mass bulimia harm avoidance personality disorders;GAD
Disease	Autism;GAD
Disease	bipolar disorder;GAD
Disease	anxiety-related temperament and behavior problems;GAD
Disease	aggression;GAD
Disease	mood response;GAD
Disease	Pervasive development disorder;FunDO
Disease	AGING;GAD
Disease	loudness dependence;GAD
Disease	auditory evoked potential;GAD
Disease	conduct disorder;GAD
Disease	violent suicidal behavior;GAD
Disease	Chronic fatigue syndrome;FunDO
Disease	alcohol abuse;GAD
Disease	PHARMACOGENOMIC;GAD
Disease	panic disorder;GAD
Disease	anxiety symptoms;GAD
Disease	METABOLIC;GAD
Disease	alcoholism;GAD
Disease	Autistic disorder;FunDO
Disease	diabetes, type 2;GAD
Disease	pathological gambling;GAD
Disease	CARDIOVASCULAR;GAD
Disease	cardiovascular;GAD
Disease	Generalized anxiety disorder;FunDO
Disease	Fibromyalgia;FunDO
Disease	anorexia nervosa and food intake;GAD
Disease	illegal drug use;GAD
Disease	Chronic obstructive airway disease;FunDO
Disease	REPRODUCTION;GAD
Disease	impulse control disorder;GAD
Disease	alcohol abuse substance abuse;GAD
Disease	Obesity;FunDO
Disease	Anorexia nervosa;FunDO
Disease	alcohol intake;GAD
Disease	Anxiety traits;GAD
Disease	migraine with aura;GAD
Disease	anxiety disorder;GAD
Disease	Neurotic disorder;FunDO
Disease	introversion and neuroticism;GAD
Disease	depression;GAD
Disease	Congenital heart disease;FunDO
Disease	obesity;GAD
Disease	delirium tremens;GAD
Disease	migraine;GAD
Disease	gastrointestinal disorders;GAD
Disease	schizotypal traits;GAD
Disease	SIDS/sudden infant death syndrome;GAD
Disease	Dementia;GAD
Disease	Depression, Postpartum;GAD
Disease	obsessive compulsive disorder;GAD
Disease	hyperkinetic disorder;GAD
Disease	Pulmonary hypertension;FunDO
Disease	Stroke;FunDO
Disease	cognitive ability;GAD
Disease	Epilepsy;FunDO
Disease	dance performance;GAD
Disease	suicide, alcohol-dependent;GAD
Disease	agreeableness;GAD
Disease	CHEMDEPENDENCY;GAD
Disease	neuroticism;GAD
Disease	Behavior disease;FunDO
Disease	Myocardial Infarction;GAD
Disease	Weight Loss;GAD
Disease	NEUROLOGICAL;GAD
Disease	citalopram adverse effects depressive disorder, major;GAD
Disease	attention-deficit hyperactivity disorder;GAD
Disease	Heart failure;FunDO
Disease	affective psychoses;GAD
Disease	auditory-evoked potentials;GAD
Disease	Fibromyalgia;GAD
Disease	violent suicide;GAD
Disease	suicidal behavior;GAD
Disease	mood disorder;GAD
External Links
Links to Entrez Gene	6532
Links to all GeneRIF Items	6532
Links to iHOP	6532
Sequence Information
Nucleotide Sequence	>6532 : length: 1893 atggagacgacgcccttgaattctcagaagcagctatcagcgtgtgaagatggagaagat tgtcaggaaaacggagttctacagaaggttgttcccaccccaggggacaaagtggagtcc gggcaaatatccaatgggtactcagcagttccaagtcctggtgcgggagatgacacacgg cactctatcccagcgaccaccaccaccctagtggctgagcttcatcaaggggaacgggag acctggggcaagaaggtggatttccttctctcagtgattggctatgctgtggacctgggc aatgtctggcgcttcccctacatatgttaccagaatggagggggggcattcctcctcccc tacaccatcatggccatttttgggggaatcccgctcttttacatggagctcgcactggga cagtaccaccgaaatggatgcatttcaatatggaggaaaatctgcccgattttcaaaggg attggttatgccatctgcatcattgccttttacattgcttcctactacaacaccatcatg gcctgggcgctatactacctcatctcctccttcacggaccagctgccctggaccagctgc aagaactcctggaacactggcaactgcaccaattacttctccgaggacaacatcacctgg accctccattccacgtcccctgctgaagaattttacacgcgccacgtcctgcagatccac cggtctaaggggctccaggacctggggggcatcagctggcagctggccctctgcatcatg ctgatcttcactgttatctacttcagcatctggaaaggcgtcaagacctctggcaaggtg gtgtgggtgacagccaccttcccttatatcatcctttctgtcctgctggtgaggggtgcc accctccctggagcctggaggggtgttctcttctacttgaaacccaattggcagaaactc ctggagacaggggtgtggatagatgcagccgctcagatcttcttctctcttggtccgggc tttggggtcctgctggcttttgctagctacaacaagttcaacaacaactgctaccaagat gccctggtgaccagcgtggtgaactgcatgacgagcttcgtttcgggatttgtcatcttc acagtgctcggttacatggctgagatgaggaatgaagatgtgtctgaggtggccaaagac gcaggtcccagcctcctcttcatcacgtatgcagaagcgatagccaacatgccagcgtcc actttctttgccatcatcttctttctgatgttaatcacgctgggcttggacagcacgttt gcaggcttggagggggtgatcacggctgtgctggatgagttcccacacgtctgggccaag cgccgggagcggttcgtgctcgccgtggtcatcacctgcttctttggatccctggtcacc ctgacttttggaggggcctacgtggtgaagctgctggaggagtatgccacggggcccgca gtgctcactgtcgcgctgatcgaagcagtcgctgtgtcttggttctatggcatcactcag ttctgcagggacgtgaaggaaatgctcggcttcagcccggggtggttctggaggatctgc tgggtggccatcagccctctgtttctcctgttcatcatttgcagttttctgatgagcccg ccacaactacgacttttccaatataattatccttactggagtatcatcttgggttactgc ataggaacctcatctttcatttgcatccccacatatatagcttatcggttgatcatcact ccagggacatttaaagagcgtattattaaaagtattaccccagaaacaccaacagaaatt ccttgtggggacatccgcttgaatgctgtgtaa
Protein Sequence	>6532 : length: 630 METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT PGTFKERIIKSITPETPTEIPCGDIRLNAV